Gastrointestinal Cancer

Gastrointestinal (GI) cancers have the highest incidence and are the second leading cause of cancer deaths in the United States (after lung cancer). At Alfa Cytology, our team of seasoned biological experts has dedicated themselves to unraveling the intricate mechanisms underlying gastrointestinal cancer development and progression.

Introduction to Gastrointestinal Cancer

Gastrointestinal (GI) cancers, encompassing a diverse range of malignancies affecting the digestive system, pose a significant global health challenge. These complex and often aggressive diseases, which include cancers of the esophagus, stomach, small intestine, colon, rectum, and liver, account for a substantial proportion of cancer-related morbidity and mortality worldwide. The heterogeneity of GI cancers, marked by their varied etiologies, and molecular profiles, has long hindered the development of comprehensive treatment strategies.

Cancer site	Estimated new cases			Estimated deaths
Cancer site	Both sexes	Male	Female	Both sexes	Male	Female
Digestive system	353,820	197,390	156,430	174,320	100,310	74,010
Esophagus	22,370	17,690	4,680	16,130	12,880	3,250
Stomach	26,890	16,160	10,730	10,880	6,490	4,390
Small intestine	12,440	6730	5,710	2,090	1,150	940
Colon & rectum	152,810	81,540	71,270	53,010	28,700	24,310
Colon	106,590	54,210	52,380
Rectum	46,220	27,330	18,890
Anus, anal canal, & anorectum	10,540	3360	7,180	2,190	1,000	1,190
Liver & intrahepatic bile duct	41,630	28,000	13,630	29,840	19,120	10,720
Gallbladder & other biliary	12,350	5,900	6,450	4,530	1,950	2,580
Pancreas	66,440	34,530	31,910	51,750	27,270	24,480
Other digestive organs	8,350	3,480	4,870	3,900	1,750	2,150

The gastrointestinal cancer treatment market is poised for substantial growth, driven by the rising incidence of GI cancers, the unmet clinical needs, and the relentless pursuit of more effective and personalized therapeutic solutions. According to industry analysts, the global GI cancer treatment market is projected to reach over $70 billion by 2028, expanding at a robust CAGR of 8.2% during the forecast period. The complex and multifaceted nature of GI cancers, coupled with the limitations of existing treatment modalities, has fueled the demand for innovative approaches that can overcome drug resistance and enhance quality of life.

Our Services

This surge in market size underscores the increasing demand for effective and innovative therapy solutions for gastrointestinal cancer. Committed to staying at the forefront of the rapidly evolving field of gastrointestinal cancer research, Alfa Cytology continuously invests in the development of innovative technologies and the expansion of its service offerings.

Anal Cancer

Bile Duct Cancer

Colorectal Cancer

Esophagus Cancer

Gallbladder Cancer

Gastrointestinal Stromal Tumor

Liver Cancer

Pancreatic Cancer

Small Intestine Cancer

Stomach Cancer

Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our preclinical services encompass a wide range of capabilities, including cell line development, high-throughput screening, pharmacokinetic and pharmacodynamic evaluations, and advanced animal models. For more information about our gastrointestinal cancer research services and how we can support your drug development initiatives, please don't hesitate to contact us.

For research use only.